Previous 10 | Next 10 |
NEW YORK , April 17, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pfenex Inc. ("Pfenex" or "the Company") (NASDAQ: PFNX). Investors who purchased Pfenex securities&...
Gainers: Comstock Holding Companies (NASDAQ: CHCI ) +111% . More news on: Comstock Holding Companies, Inc., ShiftPixy, Inc., Applied DNA Sciences, Inc., Stocks on the move, , Read more ...
Pfenex (NYSEMKT: PFNX ) announces that the FDA informed commercialization partner Alvogen Malta Operations Ltd. that it needs additional comparative use human factors data regarding PKF708, its biosimilar candidate to Eli Lilly's (NYSE: LLY ) osteoporosis med Forteo (teriparatide injection...
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA), informed Alvogen Malta Operations Ltd., the Company’s commercialization partner for PF708, via a General Advice letter that additional com...
Image source: The Motley Fool. Pfenex (NYSEMKT: PFNX) Q4 2019 Earnings Call Mar 11, 2020 , 4:30 p.m. ET Operator Continue reading
Pfenex Inc. (PFNX) Q4 2019 Earnings Conference Call March 11, 2020 4:30 P.M. ET Company Participants Eef Schimmelpennink - Chief Executive Officer, President, and Secretary Conference Call Participants Jason Butler - JMP Securities LLC Brandon Folkes - Cantor Fitzgerald &...
Pfenex (NYSEMKT: PFNX ): FY GAAP EPS of $0.03 beats by $0.13 . More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Alvogen is preparing for commercial launch of PF708 upon receiving FDA decision on therapeutic equivalence to Forteo® Jazz initiated a pivotal Phase 2/3 Study for FDA fast track designated PF743 (JZP-458) for the treatment of ALL/LBL Earned $31.1 million in development and re...
SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019, after the market close on Wednesday, March 11, 2020. Pfenex will host a conference call and webca...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 144 weeks of public selections as part of this ongoing live forward-testing. In...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractua...
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Juan Monteverde , founder, and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Pfenex Inc. (NYSE American: PFNX ) relating to it...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately s...